Biocon Share Price Gains as It Achieves European Milestone with Pebrilzo® Biosimilar Recommendation

On September 21, 2026, Biocon Limited announced a significant regulatory achievement with the European Committee for Medicinal Products for Human Use issuing a positive opinion for its Pertuzumab biosimilar, Pebrilzo®, as per the exchange filings.  

The product is designed for HER2-positive breast cancer treatment. 

European Approval for Pebrilzo® 

The Committee for Medicinal Products for Human Use has recommended marketing authorisation for Pebrilzo®, a Pertuzumab biosimilar.  

This biosimilar is a 420 mg concentrate solution for infusion, reflecting a tailored clinical development approach by European regulators. 

Target Indication and Usage 

Pebrilzo® is specifically designed for adult patients with HER2-positive breast cancer. It is approved for use in multiple clinical stages, including locally advanced, early-stage, inflammatory, or highly recurrent metastatic cancer.  

The treatment can be combined with chemotherapy and Trastuzumab as a neoadjuvant or adjuvant therapy. 

Biocon's Global Footprint 

Biocon Limited operates as an international biopharmaceutical company, focusing on affordable and scalable generic and biosimilar therapeutics.  

The company has a commercial presence in over 120 countries, employing more than 9,500 personnel across various regions. Its manufacturing network includes 7 advanced production sites and 3 core research facilities. 

Biocon's operational portfolio includes 12 commercialised biosimilar assets and over 30 generic formulations. The company is actively developing more than 20 biosimilar programmes targeting metabolic diseases, including diabetes, obesity, immunology, and oncology. Additionally, Biocon is involved in developing complex GLP-1 peptides and small-molecule generic drugs. 

Read More: Aurobindo Pharma Share Price in Focus; USFDA Issues One Observation for Telangana Facility! 

Sustainability and Recognition 

Biocon Limited has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year. This recognition underscores the company's commitment to sustainable, ethical, and responsible growth. Investor relations and media communication are facilitated through their Bengaluru office. 

Biocon Share Price Performance 

As of September 21, 2026, at 10:53 AM, Biocon share price on NSE was trading at ₹392.00, up by 1.82% from the previous closing price. 

Conclusion 

Biocon Limited's receipt of a positive European opinion for its Pertuzumab biosimilar, Pebrilzo®, marks an important milestone. The biosimilar is intended for HER2-positive breast cancer treatment, aligning with Biocon's global strategy and operational capabilities. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.